Physician profile
Gene A Devora
NPI 1952510752
$2,926.09
in general payments reported to CMS, 2019-2025
20 companies · $997 in 2025
The $997 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $97.04 · 2021: $215 · 2022: $421 · 2023: $500 · 2024: $495 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.61 |
| Education | $143.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $678.78 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $431.20 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $384.19 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $278.18 | 2019-2025 | Tezspire, Fasenra |
| Csl Behring | $178.60 | 2019-2025 | Andembry, Hizentra, Privigen |
| Pfizer INC. | $153.84 | 2019-2025 | |
| Pharming Healthcare, INC. | $146.29 | 2020-2025 | Ruconest |
| Grifols USA, LLC | $112.66 | 2021-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $109.06 | 2020-2024 | Takhzyro, Hyqvia, Cuvitru |
| Amgen INC. | $98.48 | 2022-2025 | Tezspire |
| Genzyme Corporation | $85.27 | 2019-2023 | |
| Genentech USA, INC. | $64.26 | 2019-2023 | Xolair |
| Gc Biopharma USA, INC. | $62.83 | 2025 | Alyglo |
| Merck Sharp & Dohme LLC | $31.48 | 2021-2023 | |
| Shire North American Group INC | $27.19 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $20.26 | 2024 | Ayvakit |
| Alk-Abello, INC | $18.79 | 2024 | Histamine Positive, Timothy, Standardized, Standardized Mite D. Farinae |
| Linus Health, INC. | $16.08 | 2023 | |
| Octapharma USA, INC. | $14.47 | 2022 | |
| Hikma Pharmaceuticals USA | $14.18 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Devora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.